Evidence map›Paper›PMID 42482154›Full record

ArticleCardio-oncology (London, England)2026

ICU-onset atrial fibrillation surrogate, thrombocytopenia, and short-term outcomes in patients with cancer requiring intensive care: a retrospective ICU cohort study.

Hasan Burak Isleyen, Sevil Tugrul Yavuz, Sercan Bulut, Fatih Kizkapan, Cevahir Alioglu, Erdem Sunger, Ertugrul Okuyan

Abstract read
PubMed Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hasan Burak IsleyenDepartment of Cardiology, Nisantasi University Faculty of Medicine, Istanbul, Turkey. hasanburak.isleyen@nisantasi.edu.tr.ORCID http://orcid.org/0000-0002-4400-9715
Sevil Tugrul YavuzDepartment of Cardiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Sercan BulutDepartment of Cardiology, Bagcilar Training and Research Hospital, Istanbul, Turkey.
Fatih KizkapanDepartment of Cardiology, Bagcilar Training and Research Hospital, Istanbul, Turkey.
Cevahir AliogluDepartment of Cardiology, Faculty of Medicine Hospital, Bezmialem Vakif University, Istanbul, Turkey.
Erdem SungerDepartment of Oncology, Medipol University Faculty of Medicine Hospital, Istanbul, Turkey.
Ertugrul OkuyanDepartment of Cardiology, Medipol University Faculty of Medicine Hospital, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer and atrial fibrillation frequently coexist. Intensive care adds hemodynamic stress, organ failure, and competing bleeding risk. Whether platelet-defined thrombocytopenia modifies the association between an ICU-onset atrial fibrillation surrogate and short-term outcomes in patients with cancer remains uncertain.

methodsWe performed a secondary analysis of a retrospective ICU cohort derived from MIMIC-IV version 3.1, a de-identified critical care database with date-shifted patient timelines. Adult ICU stays with solid or hematologic malignancy were included. The exposure was an ICU-onset AF surrogate rather than adjudicated incident AF. Early thrombocytopenia was defined from the minimum platelet count within 48 h and categorized as > = 150, 100-149, 50-99, and < 50 × 10^9/L. The primary outcome was in-hospital death. Secondary outcomes were 28-day death, major bleeding identified by ICD coding, and ischemic stroke identified by ICD coding. Multivariable logistic regression tested AF-by-platelet interaction. Sensitivity models added available cancer-site, cardiovascular comorbidity, major surgery, structured anticancer medication indicators, and anticoagulation dose-class variables.

resultsAmong 9,640 cancer ICU stays, 1,788 (18.5%) met criteria for the ICU-onset AF surrogate. In-hospital death occurred in 1,724 stays (17.9%), 28-day death in 2,394 (24.8%), ICD-coded major bleeding in 1,001 (10.4%), and ICD-coded ischemic stroke in 410 (4.3%). In primary complete-case interaction models (n = 9,505), the AF-by-platelet interaction for in-hospital death was borderline (P = 0.069), with the largest mortality signal in the platelet < 50 × 10^9/L stratum (adjusted OR 1.61, 95% CI 1.09-2.37). This signal persisted after expanded adjustment (adjusted OR 1.54, 95% CI 1.04-2.27) and anticoagulation dose-class adjustment (adjusted OR 1.50, 95% CI 1.01-2.22). For ICD-coded major bleeding, the interaction was significant in the primary model (P = 0.040) and remained similar after expanded adjustment (P = 0.050); the platelet 50-99 × 10^9/L stratum showed lower adjusted odds, a finding interpreted as exploratory.

conclusionsIn this cancer ICU cohort, an ICU-onset AF surrogate was associated with short-term outcome patterns that differed across platelet strata. Severe thrombocytopenia marked the subgroup with the clearest mortality signal. Because AF, bleeding, and stroke were defined from structured data rather than adjudicated events, the findings should be interpreted as hypothesis-generating.

Indexed as

Atrial fibrillationBleedingCancerIntensive careIschemic strokeMortalityThrombocytopenia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.